Abstract: The invention relates to a method for preparing epoxy resin coated melamine hydrobromide and application thereof. The method comprises the steps of dispersing epoxy resin in a solvent and stirring the epoxy resin continuously at 10-15 DEG C, dispersing the epoxy resin evenly in the solvent, adding a curing agent, and reacting for 10-200 min with stirring; adding melamine hydrobromide and a dispersing agent, continuing to react for 10-90 min with stirring, warming to 20-90 DEG C, and continuing to react for 1-9 h; and after the reaction is over, performing filtration and drying to obtain epoxy resin coated melamine hydrobromide powder. The invention further relates to a method for enabling the epoxy resin coated melamine hydrobromide to serve as a flame retardant for enabling polypropylene to reach a V2 level. According to the method for preparing the epoxy resin coated melamine hydrobromide, the water solubility and acidity of the melamine hydrobromide are reduced, the compatibility of the melamine hydrobromide and a polymer is good, the corrosion to a processing device is reduced, and the method is simple in process and facilitates industrial production.

Abstract: The present invention discloses a hydrobromide paroxetine-sec-butyl alcohol compound and a preparation method thereof. The present invention provides the hydrobromide paroxetine-sec-butyl alcohol compound as shown in formula I. The present invention further provides the preparation method of the hydrobromide paroxetine-sec-butyl alcohol compound. The preparation method comprises the following steps: mixing hydrobromide paroxetine and sec-butyl alcohol, dissolving, and carrying out crystallization to obtain the hydrobromide paroxetine-sec-butyl alcohol compound. The hydrobromide paroxetine-sec-butyl alcohol compound can be used for preparing Alpha crystalline of the hydrobromide paroxetine, the desolvation temperature is low and the energy resources are saved during preparation, and the Alpha crystalline of the hydrobromide paroxetine is high in purity and appropriate in granularity, and is suitable for industrial production. The formula I is as shown in the specification.

Abstract: The invention relates to the technical field of medicine synthesis, and concretely relates to a preparation method for prasugrel hydrobromide. The preparation method for prasugrel hydrobromide comprises firstly dissolving or suspending prasugrel in an organic solvent, adding a protic solvent, then dropwise adding acylbromide, and finally performing crystallization, so as to obtain prasugrel hydrobromide. The preparation method helps to conveniently rapidly synthesize prasugrel hydrobromide, is simple in operation, helps to obtain the product with relatively high purity, and is applicable to industrialized large-scale production.

Abstract: The study of the anti-allergic action of hydrobromide 2-[4-(41-chlorophenyl)-2-phenyliminothiazol- 3-yl]-ethanol under the code of 6.6 has been conducted. On the model of anaphylactic shock in guinea pigs it has been found that in the prophylactic administration in the dose of 5 mg/kg the test compound exhibits the anti-allergic activity at the level of the reference medicine “Claritin” tablets in the dose of 1 mg/kg – 65% and 76%, respectively. In “Ophthalmic response to introduction of histamine” test the compound studied showed the efficacy on average at the level of 72%, and the reference medicine – 83%. The data obtained allow assuming that the marked antihistaminic properties play an important role in the mechanism of the anti-allergic action of compound 6.6. The research conducted prove the reasonability of further pharmacological study of hydrobromide 2-[4-(41- chlorophenyl)-2-phenyliminothiazol- 3-yl]-ethanol with the aim of creating an effective anti-allergic medicine.

Abstract: The present invention provides a dabigatran etexilate hydrobromide represented by a general formula (I), a hydrate and/or solvate thereof, wherein n is 1, 2 or 3. The present invention further provides a preparation method of the dabigatran etexilate hydrobromide, the hydrate and/or solvate thereof, and applications in preparation of drugs for treatment or prevention of cardiovascular diseases. The dabigatran etexilate hydrobromide of the present invention has characteristics of good stability, high water solubility, high bioavailability, and low toxic-side effect. The formula (I) is defined in the specification.

Abstract: The present invention relates to an improved formulation of danirixin in its hydrobromide salt form. This improved formulation can be an aqueous intravenous formulation containing danirixin or a lyophilized pharmaceutical solid composition containing danirixin to be reconstituted to provide a solution for intravenous administration.

Abstract: The present invention relates to a pharmaceutical composition comprising prasugrel hydrobromide and a binder.

Abstract: Regardless of pH and a solvent nature the reactions of (E)-1-(β-aroylvinyl)pyridinium bromides with hydrazine led to the formation of pyrazole derivatives. The salts reacted with thiourea via intermediate formation of 4-arylpyrimidine-2-thiol to give (Z)-2-[(β-aroylvinyl)sulfanyl]-4-arylpyrimidines. In the case of N,N'-diphenylthiourea the reaction provided 6-aryl-3-aroyl-1-phenylpyridinium bromides. Pyridine hydrobromide liberated in the reaction course has a major influence on the process chemoselectivity.

Abstract: FIELD: medicine.SUBSTANCE: invention relates to medicine, in particular to experimental pharmacology, novel biologically active compounds of general formula I, representing 2-morpholino-5-phenyl-6H-1,3,4-thiadiazin, hydrobromide (L-17); 2-morpholino-5-(4′-fluorophenyl)-6H-1,3,4-thiadiazin, hydrobromide (L-31), or general formula II: 2-amino propyl morpholino-5-phenyl-6H-1,3,4-thiadiazin, dihydrobromide (L-14); 2-amino propyl morpholino-5-(4′-fluorophenyl)-6H-1,3,4-thiadiazin, dihydrobromide (L-91) as agent for correction of experimental alloxan diabetes mellitus.EFFECT: technical outcome is above compounds at intramuscular introduction in dosage of 40 mg/kg have antidiabetics action in development of alloxan diabetes in rats.1 cl, 2 dwg, 1 tbl

Abstract: Disclosed are a crystal form of a salt of an epidermal growth factor receptor kinase inhibitor and a preparation method thereof, and in particular, the crystal forms of a hydrobromide and a phosphate of a compound of formula (I).

Abstract: Cyclic pyranopterin monophosphate (<b>1</b>), isolated from bacterial culture, has previously been shown to be effective in restoring normal function of molybdenum enzymes in molybdenum cofactor (MoCo)-deficient mice and human patients. Described here is a synthesis of <b>1</b> hydrobromide (<b>1</b>·HBr) employing in the key step a Viscontini reaction between 2,5,6-triamino-3,4-dihydropyrimidin-4-one dihydrochloride and d-galactose phenylhydrazone to give the pyranopterin (5a<i>S</i>,6<i>R</i>,7<i>R</i>,8<i>R</i>,9a<i>R</i>)-2-amino-6,7-dihydroxy-8-(hydroxymethyl)-3<i>H</i>,4<i>H</i>,5<i>H</i>,5a<i>H</i>,6<i>H</i>,7<i>H</i>,8<i>H</i>,9a<i>H</i>,10<i>H</i>-pyrano­[3,2-<i>g</i>]­pteridin-4-one (<b>10</b>) and establishing all four stereocenters found in <b>1</b>. Compound <b>10</b>, characterized spectroscopically and by X-ray crystallography, was transformed through a selectively protected tri-<i>tert</i>-butoxycarbonylamino intermediate into a highly crystalline tetracyclic phosphate ester (<b>15</b>). The latter underwent a Swern oxidation and then deprotection to give <b>1</b>·HBr. Synthesized <b>1</b>·HBr had in vitro efficacy comparable to that of <b>1</b> of bacterial origin as demonstrated by its enzymatic conversion into mature MoCo and subsequent reconstitution of MoCo-free human sulfite oxidase–molybdenum domain yielding a fully active enzyme. The described synthesis has the potential for scale up.

Abstract: High pressure and temperature trigger symmetric chemical reactions of 4,4′-bipyridine hydrobromide monohydrate (44′biPyHBr·H2O) in methanol solution. Above 0.1 GPa and 423 K, the 4,4′-bipyridinium dibromide salt (44′biPy2HBr) precipitates, while the 4,4′-bipyridine free base remains dissolved in the methanol–water mixture. At 0.35 GPa and 473 K, both pyridine moieties are N-methylated and N,N-dimethylbipyridinium dibromide (44′biPy2CH3Br) is formed. None of the high-pressure compounds of 44′biPy2HBr and 44′bPy2CH3Br are solvated, which contrasts with the strong preference of analogous 1,4-diazabicyclo[2.2.2]octane (dabco) monosalts and disalts to form solvates at high-pressure. The high-pressure reactivity of 44′biPyHBr is analogous to that of 1,4-diazabicyclo[2.2.2]octane hydrobromide (dabcoHBr); however, dabcoHBr is asymmetrically N-methylated at one amine site only. This asymmetric mono N-methylation of dabcoHBr has been associated with strong electrostatic interactions between the transannular N-atoms.